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Atherosclerosis  is  a  complex  multifactorial  process  involving  lipid  accumulation,  oxidation
and  modiﬁcation,  which  together  provoke  chronic  inﬂammation  in  the  arteries  leading  to
the  development  of  ﬁbrous  plaques  that  can  erode  or  rupture  causing  thrombosis  or  steno-
sis  [1].  Atherosclerosis  develops  progressively,  over  several  decades,  and  starting  in  the
early  teens.  The  rate  of  progression  varies  according  to  the  presence  of  risk  factors,  such
as  hypertension,  diabetes  mellitus,  tobacco  smoking,  obesity  and  genetic  predisposition,
which  affect  low-density  lipoprotein  cholesterol  (LDL-C)  particles  and  the  inﬂammatory
response  [1].  Hypercholesterolemia  constitutes  a  major  risk  factor  for  the  development  of
atherosclerosis  and  coronary  heart  disease.
Evidence  from  randomized  clinical  trials  has  unequivocally  shown  that  long-term  lipid-
lowering  treatment  with  statins  substantially  reduces  the  risk  of  cardiovascular  morbidity
and  mortality  and  the  requirement  for  coronary  intervention  [2—4].  Combined  with  the  fact
that  these  drugs  are  generally  well  tolerated  and  serious  side  effects  are  rare  [5],  statins
have  become  the  ﬁrst-line  treatment  for  lowering  LDL-C  [6].  Statins  are  potent  inhibitorsRecommandations  ;
Ézétimibe  ;
Statine
of  cholesterol  biosynthesis  through  the  reversible  inhibition  of  3-hydroxy-3-methylglutaryl-
coenzyme  (HMG-CoA)  reductase,  but  they  have  also  shown  cholesterol-independent  effects
[7].  However,  whether  these  ‘‘pleiotropic’’  effects  have  demonstrable  clinical  beneﬁts  is
as  yet  unclear  [8].
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Reduction  of  LDL-C  with  statins,  alongside  improvements
n  diet,  lifestyle  and  other  modiﬁable  risk  factors,  is  a  key
im  in  the  primary  and  secondary  prevention  of  cardiovas-
ular  disease  [6,9].  However,  residual  thromboembolic  risk
ersists  despite  aggressive  LDL-C  reduction.  Not  all  patients
chieve  the  recommended  LDL-C  treatment  targets,  which
ccording  to  the  European  Society  of  Cardiology  guide-
ines  are  <  1.8  mmol/L  (<  70  mg/dL)  or  a  reduction  >  50%  from
aseline  when  the  target  cannot  be  achieved,  in  very  high
ardiovascular  risk  patients  [9].  Furthermore,  some  patients
re  intolerant  of  statins,  including  at  the  doses  required  to
chieve  sufﬁcient  reduction  in  LDL-C.  In  such  patients,  the
ddition  of  other  non-statin  treatments  can  be  used  to  lower
DL-C  further  [9].  While  nicotinic  acid  and  bile  acid  seques-
rants,  such  as  cholestyramine,  colestipol  and  colesevelam,
mprove  the  lipid  proﬁle,  clinical  outcome  data  with  these
rug  combinations  have  either  not  been  performed,  or  have
ailed  to  demonstrate  additive  atherothrombotic  protection
ver  statin  monotherapy  [10].
Ezetimibe  is  an  alternative  non-statin  lipid-lowering
edication  that  corresponds  to  an  essential  pathophysi-
logical  mechanism  in  the  progression  of  atherosclerosis.
zetimibe  reduces  blood  cholesterol  concentrations  by
nhibiting  activity  of  the  Niemann-Pick  C1-Like  1  (NPC1L1)
eceptor,  thereby  impeding  absorption  of  cholesterol  in  the
mall  intestine,  which  in  turn  reduces  hepatic  stores  of
holesterol  and  increases  cholesterol  clearance  from  the
lood  [11,12].  Data  from  one  genetic  study  have  suggested
hat  the  effect  on  coronary  heart  disease  risk  of  reducing
DL-C  is  mediated  by  the  separate  and  combined  effects
n  NPC1L1  and  HMG-CoA  reductase  genetic  polymorphisms;
oth  have  approximately  the  same  effect  when  measured
er  unit  lower  LDL-C  concentration  [12].  Furthermore,  the
eductions  in  risk  of  coronary  heart  disease  in  this  study
ere  linearly  additive.  These  ﬁndings  led  the  authors  to
ypothesize  that  the  cardiovascular  beneﬁts  of  LDL-C  low-
ring  are  independent  of  the  mechanism  by  which  it  is
educed.  In  a  second  genetic  study,  naturally  occurring
uman  mutations  (nonsense,  splice-site,  or  frameshift  muta-
ions)  that  disrupt  NPC1L1  function  were  used  to  infer  the
otential  effects  of  ezetimibe  in  terms  of  reducing  the  risk
f  coronary  heart  disease.  The  mean  LDL-C  in  heterozy-
ous  carries  of  these  mutations  was  0.31  mmol/L  (12  mg/dL)
ower  than  that  in  non-carriers  (P  =  0.04)  and  was  associated
ith  a  relative  reduction  of  53%  in  the  risk  of  develop-
ng  coronary  heart  disease  (P  =  0.008).  These  data  support
he  hypothesis  that  drugs,  such  as  ezetimibe,  that  disrupt
PC1L1  function  will  lower  the  risk  of  coronary  heart  disease
13].
The  ﬁrst  indication  of  clinical  beneﬁts  of  the  addition
f  ezetimibe  to  a  statin  were  shown  in  the  randomized,
ouble  blind  Study  of  Heart  and  Renal  Protection  (SHARP)
14],  the  objective  of  which  was  to  determine  the  safety
nd  efﬁcacy  of  reducing  LDL-C  in  9270  patients  with  chronic
idney  disease  and  no  known  history  of  myocardial  infarc-
ion  or  coronary  revascularization.  Initially,  patients  were
andomly  assigned  to  simvastatin  20  mg  plus  ezetimibe
0  mg  daily,  simvastatin  20  mg,  or  placebo.  Patients  were
ollowed-up  for  a  median  of  4.9  years.  The  primary  out-
ome  (ﬁrst  occurrence  of  non-fatal  myocardial  infarction
r  coronary  death,  non-haemorrhagic  stroke,  or  any  arte-
ial  revascularization  procedure)  was  reduced  by  17%  (95%
J
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onﬁdence  interval  6—26%)  with  the  combination  (11.3%
or  simvastatin  plus  ezetimibe  vs.  13.4%  for  placebo;  rate
atio  0.83,  95%  conﬁdence  interval  0.74—0.94;  P  =  0.0021).
he  results  from  this  study  therefore  showed  that  lower-
ng  LDL-C  with  simvastatin  plus  ezetimibe  safely  reduced
he  risk  of  major  atherosclerotic  events  in  a  broad  range
f  patients  with  chronic  kidney  disease,  including  those  on
ialysis.
The  long-awaited  results  of  the  IMProved  Reduction  of
utcomes:  Vytorin  Efﬁcacy  International  Trial  (IMPROVE-IT)
ere  published  recently  [15].  This  multicentre,  randomized,
ouble  blind,  active-control  trial,  which  involved  18,144
oderate-  to  high-risk  stabilized  patients  with  an  acute
oronary  syndrome,  was  designed  to  test  the  hypothesis
hat  the  addition  of  ezetimibe  10  mg  to  simvastatin  40  mg
ould  translate  into  a reduction  in  cardiovascular  outcomes
elative  to  simvastatin  monotherapy.  Mean  LDL-C  concentra-
ions  were  2.4  mmol/L  (93.8  mg/dL)  at  baseline,  decreasing
o  1.4  mmol/L  (53.2  mg/dL)  in  the  simvastatin—ezetimibe
roup  and  1.8  mmol/L  (69.9  mg/dL)  in  the  simvastatin
onotherapy  group.  Consistent  values  were  obtained  over
he  entire  course  of  the  trial  for  median  time-weighted
verage  LDL-C.  After  7  years  of  follow-up,  the  addition  of
zetimibe  to  simvastatin  reduced  the  risk  of  cardiovascular
vents  (cardiovascular  death,  myocardial  infarction,  rehos-
italization  for  unstable  angina,  coronary  revascularization,
r  stroke)  by  6.4%  (32.7%  vs  34.7%; absolute  risk  difference,
.0  percentage  points;  hazard  ratio  0.936,  95%  conﬁdence
nterval,  0.89—0.99;  P  =  0.016).  This  result  was  driven  by
 statistically  signiﬁcant  reduction  in  the  risk  of  myocar-
ial  infarction  (13.1%  vs  14.8%,  P  =  0.002)  and  any  stroke
4.2%  vs  4.8%,  P  =  0.05).  IMPROVE-IT  was  therefore  the  ﬁrst
tudy  to  report  an  incremental  clinical  beneﬁt  from  the
ombination  of  ezetimibe  and  simvastatin  after  an  acute
oronary  syndrome.  The  data  also  reinforced  the  concept
hat  ‘‘lower  is  better’’  for  LDL-C,  with  an  incremental  ben-
ﬁt  in  patients  treated  below  the  target  of  1.8  mmol/L
<  70  mg/dL).
Taken  together,  this  new  evidence  lends  support  to
he  move  from  a  pure  statin  LDL-C  lowering  risk-stratiﬁed
trategy  to  a  high-intensity  treat-to-target  strategy  involv-
ng  combination  therapy  with  a  statin  and  ezetimibe,  as
ecommended  in  the  European  guidelines  on  cardiovascu-
ar  disease  prevention  [9]. In  response  to  the  publication
f  these  new  ﬁndings,  the  American  College  of  Cardiol-
gy/American  Heart  Association  guidelines  [16]  continue
o  advocate  a  net  beneﬁt  approach  to  atherosclerotic  car-
iovascular  disease  reduction,  but  which  now  extends  to
on-statin  drugs,  including  ezetimibe  and  other  LDL-C  low-
ring  drugs  currently  in  development  [17].  The  ﬁndings
rom  IMPROVE-IT  also  demonstrate  a  need  to  investigate,
n  future  large  randomized  trials,  the  potential  cardiovas-
ular  beneﬁts  of  reducing  the  LDL-C  target  to  1.3  mmol/L
<  50  mg/dL)  or  below.ean  Ferrières:  educational  grants  from  the  companies
MGEN,  AstraZeneca,  MSD  Chibret,  Sanoﬁ,  Novartis  and
ervier.
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